Patrick Neven focuses on Breast cancer, Internal medicine, Oncology, Gynecology and Tamoxifen. His research on Breast cancer concerns the broader Cancer. His Internal medicine study combines topics from a wide range of disciplines, such as Placebo and Endocrinology.
His Oncology research is multidisciplinary, relying on both Adenocarcinoma, Endocrine system, Estrogen receptor and Pathology. He has included themes like Pregnancy, Cohort study, Anastrozole, Predictive value of tests and Proportional hazards model in his Gynecology study. His studies examine the connections between Tamoxifen and genetics, as well as such issues in Endometrium, with regards to Uterus, Hysteroscopy and DNA damage.
Patrick Neven spends much of his time researching Internal medicine, Breast cancer, Oncology, Cancer and Tamoxifen. Internal medicine is a component of his Estrogen receptor, Chemotherapy, Aromatase inhibitor, Letrozole and Metastatic breast cancer studies. In his research, Debulking and Ovarian cancer is intimately related to Surgery, which falls under the overarching field of Breast cancer.
His work is dedicated to discovering how Oncology, Exemestane are connected with Everolimus and other disciplines. His Cancer study combines topics in areas such as Placebo and Clinical endpoint. The concepts of his Tamoxifen study are interwoven with issues in Endometrium, Endocrinology, Aromatase and Prospective cohort study.
Patrick Neven mainly focuses on Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer. In his study, Progressive disease is strongly linked to Gastroenterology, which falls under the umbrella field of Internal medicine. His research investigates the connection with Oncology and areas like Abemaciclib which intersect with concerns in Early breast cancer.
His research in Breast cancer is mostly concerned with Tamoxifen. His Cancer research incorporates themes from Biomarker and Estrogen. Patrick Neven has researched Metastatic breast cancer in several fields, including Cancer research, Trastuzumab and Phases of clinical research.
His scientific interests lie mostly in Internal medicine, Breast cancer, Oncology, Cancer and Fulvestrant. His study explores the link between Internal medicine and topics such as Gastroenterology that cross with problems in Progressive disease. Patrick Neven works in the field of Breast cancer, focusing on Estrogen receptor in particular.
The various areas that Patrick Neven examines in his Oncology study include Tamoxifen, Proportional hazards model, MSH2, CYP2D6 and MSH6. His work in Cancer addresses issues such as Biomarker, which are connected to fields such as Estrogen. His Fulvestrant study integrates concerns from other disciplines, such as Brief Pain Inventory, Aromatase inhibitor, Placebo and Hormone receptor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
Xiaohong R. Yang;Jenny Chang-Claude;Ellen L. Goode;Fergus J. Couch.
Journal of the National Cancer Institute (2011)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
George W. Sledge;Masakazu Toi;Patrick Neven;Joohyuk Sohn.
Journal of Clinical Oncology (2017)
Association analysis identifies 65 new breast cancer risk loci
Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley.
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
Giuseppe Viale;Meredith M. Regan;Eugenio Maiorano;Mauro G. Mastropasqua.
Journal of Clinical Oncology (2007)
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
M. Piccart;G. N. Hortobagyi;M. Campone;K. I. Pritchard.
Annals of Oncology (2014)
Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche
John R.B. Perry;Felix Day;Cathy E. Elks;Patrick Sulem.
Genome-wide association studies identify four ER negative-specific breast cancer risk loci
Montserrat Garcia-Closas;Fergus J. Couch;Sara Lindstrom;Kyriaki Michailidou.
Nature Genetics (2013)
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
Giuseppe Viale;Anita Giobbie-Hurder;Meredith M. Regan;Alan S. Coates.
Journal of Clinical Oncology (2008)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching.
Journal of Clinical Oncology (2018)
Lasofoxifene in postmenopausal women with osteoporosis.
Steven R. Cummings;Kristine E Ensrud;Pierre D. Delmas;Andrea Z. LaCroix.
The New England Journal of Medicine (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: